Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• NRAS mutations are linked to cellular transformation, but in melanoma, codon 61 alterations are most common.
• The specific mechanisms driving NRAS codon 61 mutations' predominance in melanoma remain unclear.

Purpose of the Study:

• To compare the melanoma-inducing potential of NRAS codon 61 mutations against other NRAS and KRAS mutations.
• To elucidate the molecular basis for the differential oncogenic activity of NRAS mutations in melanoma.

Main Methods:

• Development and utilization of conditional knock-in mouse models expressing specific NRAS and KRAS mutations (NrasQ61R, KrasG12D, NrasG12D).
• Assessment of melanoma susceptibility in conjunction with genetic inactivation of tumor suppressors like p16INK4a and Lkb1/Stk11.
• Biochemical analysis of NRASQ61R and NRASG12D protein function, including nucleotide binding, GTPase activity, and effector pathway engagement (PI3K, RAF).

Main Results:

• Expression of NrasQ61R or KrasG12D, coupled with p16INK4a loss, efficiently induced melanoma in vivo.
• NrasG12D expression did not promote melanoma under similar conditions.
• NrasQ61R cooperated with Lkb1/Stk11 loss to drive highly metastatic melanoma.
• Functional differences between NrasQ61R and NrasG12D were minimal in PI3K/RAF engagement, but NrasQ61R exhibited enhanced nucleotide binding, reduced GTPase activity, and increased stability.

Conclusions:

• NRASQ61R expression, unlike NRASG12D, drives melanoma formation in vivo.
• The heightened melanoma-inducing capacity of NRASQ61R is attributed to increased abundance of the active GTP-bound form, rather than altered effector pathway engagement.
• This study provides a faithful mouse model for human NRAS-mutant melanoma and explains the prevalence of NRAS codon 61 mutations in the disease.